Edence Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 05-07-2024
- Paid Up Capital ₹ 2.00 Cr
as on 05-07-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 364.82%
(FY 2022)
- Profit -267.46%
(FY 2022)
- Ebitda -257.77%
(FY 2022)
- Net Worth -1404.25%
(FY 2022)
- Total Assets -12.04%
(FY 2022)
About Edence Life Sciences
The Corporate was formerly known as Omniceutical Healthcare Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Mariwala and Nihal Mariwala serve as directors at the Company.
- CIN/LLPIN
U74999MH2020PTC346908
- Company No.
346908
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Edence Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Mariwala  | Director | 29-Sep-2020 | Current |
| Nihal Mariwala | Director | 29-Sep-2020 | Current |
Financial Performance and Corporate Structure Insights of Edence Life Sciences.
Edence Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 364.82% increase. The company also saw a substantial fall in profitability, with a 267.46% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1404.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edence Life Sciences?
In 2021, Edence Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shellac And Forest Products Export Promotion CouncilActive 67 years 6 monthsSanjay Mariwala is a mutual person
Destinations Unplugged Travels Services Private LimitedActive 11 years 6 monthsNihal Mariwala is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Edence Life Sciences?
Edence Life Sciences has a workforce of 67 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Edence Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Edence Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
